Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Xeris Biopharma Holdings Inc XERS

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia... see more

Bullboard (NDAQ:XERS)

View:
User Avatar Image
(10)
•••
  • MikeTesterX
Post by MikeTesteron Aug 03, 2024 11:24am

Xeris Biopharma (XERS) Delivers Impressive Q1 2024 Results,

https://beyondspx.com/2024/08/02/xeris-biopharma-xers-delivers-impressive-q1-2024-results-raises-full-year-guidance/
Post by WakeUPPon Jun 25, 2021 9:34am

GOING UP and NO ONE HERE

sh NOOBs are still fretting away on FAILED stock promos lol lol
Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities